After hours:
Chart Events
Performance Outlook
| Previous Close | 102.03 |
| Open | 102.39 |
| Bid | 106.47 x 800 |
| Ask | 108.80 x 1300 |
| Day's Range | 102.39 - 110.50 |
| 52 Week Range | 95.50 - 188.99 |
| Volume | |
| Avg. Volume | 685,714 |
| Market Cap | 26.049B |
| Beta (5Y Monthly) | 0.18 |
| PE Ratio (TTM) | 5.34 |
| EPS (TTM) | 20.34 |
| Earnings Date | Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 02, 2022 |
| 1y Target Est | 161.41 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BNTX
Related Research
- BioNTech SEAnalyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.RatingFair ValueEconomic Moat2 months agoMorningstar
Motley FoolWhy Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Motley FoolWhy CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
CNW GroupPfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the companies' Omicron XBB.1.5-adapted monovalent COVID-19 vaccine (COMIRNATY® Omicron XBB.1.5) for ages 6 months and older. The updated vaccine will be available in Canada as a single dose for individuals 5 years of age and older, regardless of prior COVID-19 vaccination history. For children 6 months through 4 years of age, the updated vaccine is authorized for administration as a thr
